Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Macrophage Rac2 is required to reduce the severity of cigarette smoke-induced pneumoniaAmerican Journal of Respiratory and Critical Care Medicine.  198:1288-1301. 2018
2013 Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticlesActa Biomaterialia.  9:8262-8271. 2013
2011 Elicitation of mucosal immunity by proteins of streptococcus pneumoniae 2011
2011 Heat-shock protein ClpL/HSP100 increases penicillin tolerance in streptococcus pneumoniae 2011
2011 Protection of pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A 2011
2011 Decrease in penicillin susceptibility due to heat shock protein ClpL in Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy.  55:2714-2728. 2011
2010 Effect of apolactoferrin on experimental pneumococcal otitis media 2010
2010 Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy.  54:707-717. 2010
2009 Virulence of pneumococcal proteins on the inner ear 2009
2008 The round window membrane in otitis media: Effect of pneumococcal proteins 2008
2008 Macrophage turnover kinetics in the lungs of mice infected with Streptococcus pneumoniaeAmerican Journal of Respiratory Cell and Molecular Biology.  38:105-113. 2008
2007 Importance of phosphoinositide 3-kinase γ in the host defense against pneumococcal infectionAmerican Journal of Respiratory and Critical Care Medicine.  175:958-966. 2007
2006 Bacterial interference of penicillin-sensitive and -resistant Streptococcus pneumoniae by Streptococcus oralis in an adenoid organ culture: Implications for the treatment of recurrent upper respiratory tract infections in children and adults 2006
2000 Pathway analysis in metabolic databases via differential metabolic display (DMD)Bioinformatics.  16:825-836. 2000
2000 Production and characterization of the functional fragment of pneumococcal surface protein AArchives of Biochemistry and Biophysics.  373:116-125. 2000
1996 Systemic and mucosal protective immunity to pneumococcal surface protein AAnnals of the New York Academy of Sciences.  797:118-126. 1996
1994 Cross‐Reactive Protection Eliciting Epitopes of Pneumococcal Surface Protein AAnnals of the New York Academy of Sciences.  730:361-363. 1994
1991 Antigen-Independent Selection of T15 Idiotype During B-Cell Ontogeny in MiceAutoimmunity.  1:203-212. 1991
1989 Age-related change in anti-carbohydrate antibody levelsAmerican Journal of Epidemiology.  129:89-96. 1989
1983 DEFICIENT IgA SYNTHESIS VIEWED IN THE CONTEXT OF NORMAL DEVELOPMENT OF IgA B‐CELLSAnnals of the New York Academy of Sciences.  409:461-468. 1983

Chapter

Year Title Altmetric
2019 Pneumococcal Vaccines 2019
2019 Pneumococcal vaccines.  362-377. 2019
2012 Pneumococcal common proteins and other vaccine strategies..  459-469. 2012
2012 Analysis of the diversity of murine antibodies to a (1-3) dextran..  295-308. 2012
2008 Animal Models of Invasive Pneumococcal Disease.  47-58. 2008
2005 Respiratory bacterial vaccines.  905-921. 2005
2004 Pneumococcal proteins and their potential use in pneumococcal vaccines.  459-469. 2004
2003 Streptococcus pneumoniae vaccines.  294-310. 2003
2003 Immunity to Extracellular Bacteria:.  1263-1284. 2003

Research Overview

  • The Briles lab focuses on the use of virulence factors of Streptococcus pneumoniae in the development of human pneumococcal vaccines. Pneumococci are a major cause of pneumonia, serious meningitis, otitis media, sepsis, and bacteremia in man. Our approach uses both bacterial and animal genetics to identify and study important mechanisms in protection and virulence. We identified a cell surface protein of pneumococci, PspA, which is important for pneumococcal virulence and is probably the most exposed protein on the pneumococcal surface. We do pre-clinical research and collaborate on clinical research with PspA and other pneumococcal proteins that will hopefully lead to a vaccine for young children and the elderly. Studies are underway to characterize the protection-eliciting portion of PspAs from human isolates of pneumococci, and to assemble these into an effective human vaccine with other protection-eliciting pneumococcal proteins. We are/have been studying the mode of action of several pneumococcal virulence factors including PspA, pneumolysin, PspC, PsaA, PcpA, and NanA. We believe that epitopes of some of or all of these proteins will be used to create a vaccine to prevent pneumococcal carriage and invasive disease. We are also developing in vivo killing assays to guide the development of such a vaccine for use in humans. Our collaborations at UAB are primarily with the labs of M. Nahm, C. Orihuela, and W. Swords. Our work involves collaborations with vaccine development groups in Japan, China, the United Kingdom, Brazil, and Australia.
  • Principal Investigator On

  • Comparative Efficacy of Non Capsular Pneumococcal Vaccines in Animal Models  awarded by PATH VACCINE SOLUTIONS
  • Comparative Efficacy of Non Capsular Pneumococcal Vaccines in Animal Models - Fifth Project Plan  awarded by PATH VACCINE SOLUTIONS
  • Comparative Efficacy of Non Capsular Pneumococcal Vaccines in Animal Models - Fourth Project Plan  awarded by PATH VACCINE SOLUTIONS
  • Comparative Efficacy of Non Capsular Pneumococcal Vaccines in Animal Models - Third Project Plan  awarded by PATH VACCINE SOLUTIONS
  • Detection of Protective Antibody with ModOPKA Functional Assay  awarded by PATH VACCINE SOLUTIONS
  • Development of a Diagnostic Test for Pneumococcal Pneumonia  awarded by PATH FOUNDATION
  • Effect of Middle Ear Inflammation on the Inner Ear  awarded by University of Minnesota
  • Eight Project Plan - VAC-010  awarded by PATH VACCINE SOLUTIONS
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by SANOFI DIAGNOSTICS PASTEUR, INC.
  • Private Grant  awarded by GENOCEA BIOSCIENCES, INC.
  • Protection Elicited by Active Immunity to Goldstein Antigen ProtGBSP14  awarded by PATH VACCINE SOLUTIONS
  • PspA Mechanisms of Humoral Immunity, Functional Assays, and Optimal Vaccine Constructs  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • PspA: A Potential Pneumococcal Vaccine Component  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Seventh Project Plan, Rabbit Antisera to R. Goldstein's Antigens  awarded by PATH VACCINE SOLUTIONS
  • Sixth Project Plan, Detection of Protective Antibody with ModOPKA Functional Assay  awarded by PATH VACCINE SOLUTIONS
  • The Role of PcpA in the Mechanism of Virulence and Protective Immunity  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Trivalent Pneumococcal Protein Vaccine (PPC): Preclinical Optimization  awarded by PATH FOUNDATION
  • Vaccine Potential of the Proline-Rich Domain of Pneumococcal Surface Protein A  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS
  • Education And Training

  • Doctor of Philosophy in Immunology, The Rockefeller University 1973
  • Full Name

  • David Briles